And, as I just wrote below, the full FDA Commission is in no manner bound by this Advisory Committee vote — but it certainly stretches the odds on a new label in Merck’s favor, any time soon — as a result of IMPROVE-IT data.

I have only more questions — none of which will be answered until the full Commission votes next month.